The stock's fall snapped an eight-day winning streak.

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...

It’s been called the closest the world has ever come to a vaccine against the AIDS virus. The twice-yearly shot was 100% ...

In October, lenacapavir manufacturer, Gilead, announced a deal that allows six manufacturers to produce generic versions of ...

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a ...

We face a crucial decision as President-elect Trump’s team takes shape and begins to govern: whether to view other Americans ...

Catch up on all the biggest pharma news to hit the industry last month, with stories spanning the US election, new ...

Intra-Cellular Therapies ITCI announced that it has submitted a supplemental new drug application (sNDA) to the FDA aiming to ...

Timely remdesivir treatment in immunocompromised patients infected with COVID-19 is associated with improved survival outcomes.